150 related articles for article (PubMed ID: 32687367)
1. Biophysical Characterization of Binary Therapeutic Monoclonal Antibody Mixtures.
Krieg D; Berner C; Winter G; Svilenov HL
Mol Pharm; 2020 Aug; 17(8):2971-2986. PubMed ID: 32687367
[TBL] [Abstract][Full Text] [Related]
2. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.
Thiagarajan G; Semple A; James JK; Cheung JK; Shameem M
MAbs; 2016; 8(6):1088-97. PubMed ID: 27210456
[TBL] [Abstract][Full Text] [Related]
3. Thermodynamic Unfolding and Aggregation Fingerprints of Monoclonal Antibodies Using Thermal Profiling.
Melien R; Garidel P; Hinderberger D; Blech M
Pharm Res; 2020 Apr; 37(4):78. PubMed ID: 32236701
[TBL] [Abstract][Full Text] [Related]
4. Small-angle x-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4.
Tian X; Langkilde AE; Thorolfsson M; Rasmussen HB; Vestergaard B
J Pharm Sci; 2014 Jun; 103(6):1701-10. PubMed ID: 24700358
[TBL] [Abstract][Full Text] [Related]
5. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
[TBL] [Abstract][Full Text] [Related]
6. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
[TBL] [Abstract][Full Text] [Related]
7. The effect of arginine glutamate on the stability of monoclonal antibodies in solution.
Kheddo P; Tracka M; Armer J; Dearman RJ; Uddin S; van der Walle CF; Golovanov AP
Int J Pharm; 2014 Oct; 473(1-2):126-33. PubMed ID: 24992318
[TBL] [Abstract][Full Text] [Related]
8. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs.
Sjuts H; Schreuder H; Engel CK; Bussemer T; Gokarn Y
Drug Dev Res; 2020 May; 81(3):329-337. PubMed ID: 31758731
[TBL] [Abstract][Full Text] [Related]
9. High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.
Zidar M; Šušterič A; Ravnik M; Kuzman D
Pharm Res; 2017 Sep; 34(9):1831-1839. PubMed ID: 28593474
[TBL] [Abstract][Full Text] [Related]
10. Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies.
Thakkar SV; Joshi SB; Jones ME; Sathish HA; Bishop SM; Volkin DB; Middaugh CR
J Pharm Sci; 2012 Sep; 101(9):3062-77. PubMed ID: 22581714
[TBL] [Abstract][Full Text] [Related]
11. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
[TBL] [Abstract][Full Text] [Related]
12. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
13. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis.
Bommana R; Chai Q; Schöneich C; Weiss WF; Majumdar R
J Pharm Sci; 2018 Jun; 107(6):1498-1511. PubMed ID: 29408480
[TBL] [Abstract][Full Text] [Related]
15. Local dynamics and their alteration by excipients modulate the global conformational stability of an lgG1 monoclonal antibody.
Thakkar SV; Kim JH; Samra HS; Sathish HA; Bishop SM; Joshi SB; Volkin DB; Middaugh CR
J Pharm Sci; 2012 Dec; 101(12):4444-57. PubMed ID: 23060088
[TBL] [Abstract][Full Text] [Related]
16. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic monoclonal antibody.
Menzen T; Friess W
J Pharm Sci; 2014 Feb; 103(2):445-55. PubMed ID: 24382634
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
[TBL] [Abstract][Full Text] [Related]
18. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.
Neergaard MS; Kalonia DS; Parshad H; Nielsen AD; Møller EH; van de Weert M
Eur J Pharm Sci; 2013 Jun; 49(3):400-10. PubMed ID: 23624326
[TBL] [Abstract][Full Text] [Related]
19. Developability assessment for monoclonal antibody drug candidates: a case study.
Garripelli VK; Wu Z; Gupta S
Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
[TBL] [Abstract][Full Text] [Related]
20. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
